These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24189253)

  • 1. Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients.
    Zvada SP; Denti P; Sirgel FA; Chigutsa E; Hatherill M; Charalambous S; Mungofa S; Wiesner L; Simonsson US; Jindani A; Harrison T; McIlleron HM
    Antimicrob Agents Chemother; 2014; 58(1):503-10. PubMed ID: 24189253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection.
    Al-Shaer MH; Alghamdi WA; Alsultan A; An G; Ahmed S; Alkabab Y; Banu S; Barbakadze K; Houpt E; Kipiani M; Mikiashvili L; Cegielski JP; Kempker RR; Heysell SK; Peloquin CA
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited Effect of Later-Generation Fluoroquinolones in the Treatment of Ofloxacin-Resistant and Moxifloxacin-Susceptible Multidrug-Resistant Tuberculosis.
    Lee H; Ahn S; Hwang NY; Jeon K; Kwon OJ; Huh HJ; Lee NY; Kim CK; Koh WJ
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.
    Srivastava S; Deshpande D; Pasipanodya J; Nuermberger E; Swaminathan S; Gumbo T
    Clin Infect Dis; 2016 Nov; 63(suppl 3):S102-S109. PubMed ID: 27742641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis.
    Chigutsa E; Meredith S; Wiesner L; Padayatchi N; Harding J; Moodley P; Mac Kenzie WR; Weiner M; McIlleron H; Kirkpatrick CM
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3857-63. PubMed ID: 22564839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.
    Poissy J; Aubry A; Fernandez C; Lott MC; Chauffour A; Jarlier V; Farinotti R; Veziris N
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4765-71. PubMed ID: 20805388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
    Mpagama SG; Ndusilo N; Stroup S; Kumburu H; Peloquin CA; Gratz J; Houpt ER; Kibiki GS; Heysell SK
    Antimicrob Agents Chemother; 2014; 58(2):782-8. PubMed ID: 24247125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013.
    Xia H; Zheng Y; Liu D; Wang S; He W; Zhao B; Song Y; Ou X; Zhou Y; van den Hof S; Cobelens F; Zhao Y
    Microbiol Spectr; 2021 Dec; 9(3):e0040921. PubMed ID: 34851179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz Coadministration Using Population Pharmacokinetic Modeling.
    Chirehwa MT; Resendiz-Galvan JE; Court R; De Kock M; Wiesner L; de Vries N; Harding J; Gumbo T; Warren R; Maartens G; Denti P; McIlleron H
    Antimicrob Agents Chemother; 2023 Mar; 67(3):e0142622. PubMed ID: 36744891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoroquinolones for the treatment of tuberculosis in children.
    Thee S; Garcia-Prats AJ; Donald PR; Hesseling AC; Schaaf HS
    Tuberculosis (Edinb); 2015 May; 95(3):229-45. PubMed ID: 25797610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data.
    Angeby KA; Jureen P; Giske CG; Chryssanthou E; Sturegård E; Nordvall M; Johansson AG; Werngren J; Kahlmeter G; Hoffner SE; Schön T
    J Antimicrob Chemother; 2010 May; 65(5):946-52. PubMed ID: 20332195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
    Shandil RK; Jayaram R; Kaur P; Gaonkar S; Suresh BL; Mahesh BN; Jayashree R; Nandi V; Bharath S; Balasubramanian V
    Antimicrob Agents Chemother; 2007 Feb; 51(2):576-82. PubMed ID: 17145798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline resistance and cross-resistance among fluoroquinolones in multidrug-resistant Mycobacterium tuberculosis isolates at a national reference laboratory in India.
    Mamatha HG; Shanthi V
    J Glob Antimicrob Resist; 2018 Mar; 12():5-10. PubMed ID: 28887289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug-resistant tuberculosis therapy.
    Boonpeng A; Jaruratanasirikul S; Wattanavijitkul T; Nawakitrangsan M; Samaeng M
    Biopharm Drug Dispos; 2021 Jul; 42(7):329-337. PubMed ID: 34117648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of moxifloxacin resistance in clinical Mycobacterium tuberculosis isolates in Houston, Texas.
    El Sahly HM; Teeter LD; Jost KC; Dunbar D; Lew J; Graviss EA
    J Clin Microbiol; 2011 Aug; 49(8):2942-5. PubMed ID: 21653760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using Mycobacterium tuberculosis Single-Nucleotide Polymorphisms To Predict Fluoroquinolone Treatment Response.
    Seifert M; Capparelli E; Catanzaro DG; Rodwell TC
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31085512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes.
    Lee J; Lee CH; Kim DK; Yoon HI; Kim JY; Lee SM; Yang SC; Lee JH; Yoo CG; Lee CT; Chung HS; Kim YW; Han SK; Yim JJ
    Korean J Intern Med; 2011 Jun; 26(2):153-9. PubMed ID: 21716591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations.
    Sarathy J; Blanc L; Alvarez-Cabrera N; O'Brien P; Dias-Freedman I; Mina M; Zimmerman M; Kaya F; Ho Liang HP; Prideaux B; Dietzold J; Salgame P; Savic RM; Linderman J; Kirschner D; Pienaar E; Dartois V
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30803965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.
    Peloquin CA; Hadad DJ; Molino LP; Palaci M; Boom WH; Dietze R; Johnson JL
    Antimicrob Agents Chemother; 2008 Mar; 52(3):852-7. PubMed ID: 18070980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability.
    Gumbo T
    Antimicrob Agents Chemother; 2010 Apr; 54(4):1484-91. PubMed ID: 20086150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.